Shield Therapeutics PLC Grant of share options to the CEO (9982B)

TIDMSTX

RNS Number : 9982B

Shield Therapeutics PLC

15 June 2021

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

Grant of share options to the Chief Executive Officer

London, UK, 15 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) (ferric maltol), announces that on 14 June 2021 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under Shield Therapeutics' Retention and Performance Share Plan ("RPSP").

In accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to Greg Madison who is deemed a PDMR:

 
     Name       Option Plan   Number of Ordinary Shares under Option                    Vesting Date 
 Greg Madison      RPSP                      620,696                   Dependent on performance conditions outlined 
                                                                       below, vesting occurs on 14 June 2024. 
               ------------  ---------------------------------------  ------------------------------------------------ 
 Greg Madison      RPSP                     1,000,000                  Vesting occurs on 1 June 2022 and is not 
                                                                       subject to performance conditions but is 
                                                                       subject 
                                                                       to Mr Madison remaining in office as at the 
                                                                       date of vesting. 
               ------------  ---------------------------------------  ------------------------------------------------ 
 

These awards are subject to the following performance conditions:

1. The basis of the performance measurement in respect of the 620,696 options is based solely on the share price movement over 365 days following the date of grant. The baseline share price ("Baseline Share Price") has been set at GBP0.57 which is the average of the closing prices of the Company's Ordinary Shares over the 5 business days leading up to and including the 14 June 2021 date of grant. Therefore, the performance measurement will be assessed on 14 June 2022. The share price measurement will be the average of the closing prices of the Company's Ordinary Shares over the 5 business days leading up to and including 14 June 2022 (the performance measurement date). In normal circumstances the shares will vest on 14 June 2024.

2. The proportion of the 620,696 options subject to performance conditions (the "Performance Awards") that will Vest will be subject to the following measurements:

a. Should the share price increase by 10% or less over the Baseline Share Price then no Performance Awards will Vest.

b. Should the share price increase by more than 50% over the Baseline Share Price then 100% of the Performance Awards will Vest.

c. Should the share price increase by between 10% and 50% over the Baseline Share Price then a proportional calculation will be used to calculate the percentage of the Performance Awards that will Vest.

   d.    Examples of this proportional Vesting is detailed below: 

i. Should the share price increase by between 11% and 19% over the Baseline Share Price, 2.5% of the Performance Awards will Vest.

ii. Should the share price increase by between 20% and 29% over the Baseline Share Price, 25% of the Performance Awards will Vest.

iii. Should the share price increase by between 30% and 39% over the Baseline Share Price, 50% of the Performance Awards will Vest.

iv. Should the share price increase by between 40% and 49% over the Baseline Share Price, 75% of the Performance Awards will Vest.

Mr Madison does not currently hold any ordinary shares in the Company.

 
 1.   Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated 
       with them ("PCA") 
 a)   Name                                      Greg Madison 
     ----------------------------------------  ----------------------------------------------------------------------- 
 2.   Reason for the notification 
     ----------------------------------------------------------------------------------------------------------------- 
 a)   Position/status                           Chief Executive Officer 
     ----------------------------------------  ----------------------------------------------------------------------- 
 b)   Initial notification/                     Initial Notification 
       amendment 
     ----------------------------------------  ----------------------------------------------------------------------- 
 3.   Details of the Issuer 
     ----------------------------------------------------------------------------------------------------------------- 
 a)   Name                                      Shield Therapeutics plc 
     ----------------------------------------  ----------------------------------------------------------------------- 
 b)   LEI code                                  213800G74QWY15FC3W71 
     ----------------------------------------  ----------------------------------------------------------------------- 
 4.   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
     ----------------------------------------------------------------------------------------------------------------- 
 a)   Description of the financial instrument   Options over new Ordinary Shares 
 
       Identification code 
                                                 ISIN: GB00BYV81293 
     ----------------------------------------  ----------------------------------------------------------------------- 
 b)   Nature of the transaction                 Grant of awards over new Ordinary Shares under the Company's Retention 
                                                and Performance Share 
                                                Plan. 
     ----------------------------------------  ----------------------------------------------------------------------- 
 c)   Price(s) and volumes(s)                   2021 RPSP Award 
                                                  Price (GBP)   Volume 
                                                  0.015         1,620,696 
                                                               ---------- 
     ----------------------------------------  ----------------------------------------------------------------------- 
 d)        Aggregated information 
             *    Aggregate volume                Awards granted over 1,620,696 shares in total 
 
                                                  1.5p exercise price 
 
             *    Price 
     ----------------------------------------  ----------------------------------------------------------------------- 
 e)   Date of the transaction                   14 June 2021 
     ----------------------------------------  ----------------------------------------------------------------------- 
 f)   Place of the transaction                  Outside of trading venue 
     ----------------------------------------  ----------------------------------------------------------------------- 
 

For further information please contact:

 
 Shield Therapeutics plc                              www.shieldtherapeutics.com 
 Greg Madison, CEO                                           [phone] 
 Lucy Huntington-Bailey, Company 
  Secretary and General Counsel                              [phone] 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                     [phone] 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                      [phone] 
 
 
   Financial PR & IR Advisor 
 Walbrook PR                        [phone] or [e-mail] 
                                           [phone] / [phone] 
 Paul McManus/Lianne Cawthorne                                               303 
 
 

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSFFFIIEFSEDM

(END) Dow Jones Newswires

June 15, 2021 13:15 ET (17:15 GMT)